Henlius (2696.HK) announced its annual results for the year ended December 31, 2025, reporting a revenue of RMB 6.6666 billion, a 16.5% year-on-year increase, and a net profit of RMB 0.8270 billion. The company's R&D investment reached RMB 2.4919 billion, up 35.4%, with pre-R&D profit growing 26.2% to RMB 2.3425 billion. This marks the third consecutive year of profitability and sustained revenue growth since 2023. Global product revenue increased by 17.0% to RMB 5.7746 billion. Notably, ex-China product revenue exceeded RMB 200 million, doubling year-on-year, with ex-China product profit reaching RMB 93.9 million. Henlius has secured approvals for 10 products in 60 countries and regions.
Henlius demonstrates sustained financial health and global expansion, with significant growth in both revenue and profit. The substantial increase in R&D investment signals a commitment to future innovation, while the doubling of ex-China revenue highlights successful international market penetration for its core products, indicating a strong trajectory for global biopharmaceutical growth.
Henlius reported RMB 6.6666 billion in revenue for 2025, a 16.5% year-on-year increase.
Net profit for 2025 was RMB 0.8270 billion, marking the third consecutive year of profitability.
Ex-China product revenue doubled to over RMB 200 million in 2025.
The results highlight Henlius's growing presence and success in international markets, particularly with its ex-China revenue doubling, indicating a strong expansion beyond its domestic base in China.
Ex-China product revenue doubled to over RMB 200 million in 2025.
R&D investment increased by 35.4% to RMB 2.4919 billion.
Sign in to save notes on signals.
Sign In